Back HIV/Hepatitis Coinfection

Coinfection

AASLD 2016: Sofosbuvir/ Ledipasvir Effective for HIV/HCV Coinfected People in Real-World Cohorts

The sofosbuvir/ledipasvir (Harvoni) coformulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people coinfected with hepatitis C, according to a pooled analysis presented at the 2016 AASLD Liver Meeting this month in Boston.

alt

Read more:

AASLD 2016: HIV/HCV Coinfected People See Good Cure Rates in Real-World Practice in Madrid

More than 90% of HIV-positive people treated with direct-acting antivirals for hepatitis C -- including many with liver cirrhosis -- achieved sustained virological response and few discontinued treatment due to side effects, showing that real-world clinical practice can produce results as good as those seen in formal clinical trials, according to results from a Spanish study presented at the AASLD Liver Meeting this month in Boston.

alt

Read more:

AIDS 2016: Sofosbuvir/ Velpatasvir Shows High Cure Rate in HIV/HCV Coinfection Study

The once-daily coformulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes and was safe and well tolerated by HIV/HCV coinfected patients in the ASTRAL-5 trial, according to results presented at the 21st International AIDS Conference (AIDS 2016)this week in Durban. A related analysis showed that sofosbuvir/velpatasvir can be safely combined with most widely used antiretrovirals, with the exception of efavirenz.

alt

Read more:

Improved HIV Treatment Has Not Reduced End-Stage Liver Disease in HIV/HCV Coinfected People

Incidence of end-stage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the U.S. report in the November 1 edition of Clinical Infectious Diseases

alt

Read more:

Incidence of Liver Cancer Is Increasing Among People with HIV/HCV Coinfection

Incidence of liver cancer is increasing among people with HIV co-infection, an international team of investigators report in the June 15 online edition of Clinical Infectious Diseases. Researchers from Europe and Canada pooled data gathered between 2001 and 2014 from 6 prospective cohorts and found that incidence of hepatocellular carcinoma (HCC) increased, but the incidence of serious liver related events -- decompensated liver disease or liver-related death -- declined.

alt

Read more:

AIDS 2016: Ongoing Hepatitis B Virus Replication Raises Mortality for People with HIV

People with HIV and hepatitis B virus (HBV) coinfection have more than double the risk of death if they have ongoing high-level HBV replication, indicating a need for prompt treatment, according to an analysis from the Temprano trial presented at an HIV and viral hepatitis coinfection session at the 21st International AIDS Conference (AIDS 2016) last month in Durban.

alt

Read more:

EASL 2016: Does Having HIV Affect Response to Hepatitis C Treatment?

A study from the U.S. Veterans Health Administration found that HIV-positive people responded as well as those without HIV to direct-acting antiviral (DAA) therapy for hepatitis C, while a Spanish study showed that HIV/HCV coinfected people were less likely to be cured. These conflicting findings, presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona, indicate that the interactions between HIV and hepatitis C are still not fully understood.alt

Read more:

AIDS 2016: AbbVie 3D and 2D Hepatitis C Combos Work Well for HIV/HCV Coinfected People

AbbVie's paritaprevir-based 3D regimen for hepatitis C virus (HCV) genotype 1 and 2D regimen for genotype 4 were shown to be highly effective and well-tolerated for HIV-positive people with HCV coinfection in the TURQUOISE-I trial, according to a report at the 21st International AIDS Conference last week in Durban.

alt

Read more:

EASL 2016: Sofosbuvir/ Velpatasvir Cures 95% of HIV/HCV Coinfected People

A dual regimen of sofosbuvir plus velpatasvir was well-tolerated and highly effective against hepatitis C virus (HCV) genotypes 1 through 4 in HIV-positive people with chronic hepatitis C coinfection, according to results from the Phase 3 ASTRAL-5 trial presented at the 2016 EASL International Liver Congress last week in Barcelona.

alt

Read more: